Paraganglioma as a risk factor for bone metastasis

Area of Science:

• Oncology
• Endocrinology
• Skeletal Metastasis

Background:

• Malignant pheochromocytoma (PHEO) and paraganglioma (PGL), collectively known as PPGL, commonly present with bone metastasis.
• Bone metastasis significantly impacts patient quality of life (QOL) by necessitating long-term management and potentially causing skeletal-related events (SREs).

Purpose of the Study:

• To identify risk factors associated with the development of bone metastasis in patients diagnosed with PPGL.
• To understand the predictors of skeletal-related events (SREs) in PPGL patients with bone metastasis.

Main Methods:

• Retrospective review of medical records from 40 adult patients with malignant PPGL treated between 2006 and 2016.
• Analysis of metastasis sites, with a focus on bone, and correlation with tumor type (PHEO vs. PGL) and occurrence of SREs.
• Definition of SREs included pathologic fracture, spinal cord compression, and the need for bone irradiation or surgery.

Main Results:

• Bone was the most common site of metastasis (60%), with PGL patients (80%) showing higher rates than PHEO patients (40%) (p=0.02).
• Half of the patients with bone metastasis experienced at least one SRE.
• Extra-skeletal invasion of the spine was significantly more frequent in patients with bone metastasis who also had SREs (p=0.001).

Conclusions:

• Paraganglioma (PGL) is a key risk factor for bone metastasis in PPGL patients.
• Extra-skeletal invasion of the spine is a critical risk factor for developing SREs in PPGL patients with bone metastasis.
• Targeted surveillance and management strategies are crucial, particularly for PGL patients and those with spinal invasion.